AbbVie Inc. $ABBV Stake Lifted by USS Investment Management Ltd

USS Investment Management Ltd lifted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 3.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 298,983 shares of the company’s stock after acquiring an additional 9,950 shares during the quarter. USS Investment Management Ltd’s holdings in AbbVie were worth $65,015,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Procyon Advisors LLC raised its position in AbbVie by 19.9% in the fourth quarter. Procyon Advisors LLC now owns 32,752 shares of the company’s stock worth $7,484,000 after acquiring an additional 5,427 shares in the last quarter. Waycross Partners LLC boosted its position in shares of AbbVie by 2.9% during the 4th quarter. Waycross Partners LLC now owns 182,476 shares of the company’s stock valued at $41,694,000 after purchasing an additional 5,063 shares in the last quarter. Calamos Advisors LLC boosted its position in shares of AbbVie by 3.4% during the 4th quarter. Calamos Advisors LLC now owns 466,290 shares of the company’s stock valued at $106,543,000 after purchasing an additional 15,458 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of AbbVie by 11.7% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 636,710 shares of the company’s stock worth $143,026,000 after purchasing an additional 66,720 shares during the last quarter. Finally, Victory Capital Management Inc. grew its stake in shares of AbbVie by 8.6% in the 3rd quarter. Victory Capital Management Inc. now owns 1,525,632 shares of the company’s stock worth $350,656,000 after purchasing an additional 120,490 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

AbbVie stock opened at $251.45 on Wednesday. The firm’s 50 day simple moving average is $216.92 and its 200-day simple moving average is $219.56. The company has a market cap of $444.26 billion, a P/E ratio of 123.87, a price-to-earnings-growth ratio of 0.78 and a beta of 0.32. AbbVie Inc. has a fifty-two week low of $184.38 and a fifty-two week high of $255.99.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter in the prior year, the firm earned $2.46 EPS. The firm’s quarterly revenue was up 12.4% on a year-over-year basis. On average, analysts expect that AbbVie Inc. will post 14.28 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. AbbVie’s dividend payout ratio is presently 340.89%.

Analysts Set New Price Targets

Several research firms recently commented on ABBV. Piper Sandler reissued an “overweight” rating and set a $298.00 target price on shares of AbbVie in a research note on Tuesday, June 23rd. Wells Fargo & Company set a $260.00 price target on shares of AbbVie in a research report on Monday, June 22nd. BMO Capital Markets reiterated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Finally, William Blair reissued an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $253.81.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie and Genmab reported positive Phase 3 results for Epkinly/epcoritamab in relapsed or refractory diffuse large B-cell lymphoma, with the trial meeting its primary endpoint and suggesting a potential label expansion. Article Title
• Positive Sentiment: AbbVie received positive CHMP opinions in Europe for Rinvoq in severe alopecia areata and non-segmental vitiligo, which could broaden the drug’s addressable market and add future sales momentum if approved. Article Title
• Positive Sentiment: AbbVie’s newly announced $10.9 billion Apogee acquisition and other partnership milestones underscore management’s willingness to invest heavily in future growth and deepen its immunology and neurology pipeline. Article Title
• Neutral Sentiment: Analysts slightly trimmed FY2026 earnings estimates, but the revised forecast remains close to consensus, so this looks like a modest rather than a major headwind. Article Title
• Negative Sentiment: U.S. lawmakers opened an investigation into AbbVie’s clinical trials in China, citing possible national security, ethical, and data-protection concerns. Article Title

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.